---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product comparison"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Product comparison. Topics: Summary: lorundrostat and the add-on options for uncontrolled hypertension; Lorundrostat: Launch-HTN primary endpoint, for comparison with the add-on drugs below; Baxdrostat (BAXFENDY, AstraZeneca): FDA approval, May 2026; Baxdrostat (BAXFENDY): prescribing information; 27 further topics. 31 evidence topics quoted from 33 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Summary: lorundrostat and the add-on options for uncontrolled hypertension

- Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
- Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
- Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
- Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.

Source: [FDA NDA 219878 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf); [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf); [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf); [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf); [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf); [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023); [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Tsou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13587145/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-2"></a>

### Lorundrostat: Launch-HTN primary endpoint, for comparison with the add-on drugs below

> “For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.14-3"></a>

### Baxdrostat (BAXFENDY, AstraZeneca): FDA approval, May 2026

> “This NDA provides for the use of Baxfendy (baxdrostat) tablets for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
> “It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”
> “05/15/2026”

Source: [FDA NDA 219878 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf)

> “AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.”

Source: [AstraZeneca press release, BAXFENDY US approval (2026)](https://www.businesswire.com/news/home/20260518258445/en/)

<a id="topic-2.1.2.14-4"></a>

### Baxdrostat (BAXFENDY): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.” |
| Recommended dosage | “The recommended dosage of BAXFENDY is 2 mg orally once daily.” |
| Dosage at increased risk of hyperkalemia or hyponatremia | “For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily” |
| Strengths | “Tablets: 1 mg and 2 mg” |
| Contraindications | “None.” |
| Warnings and precautions | “Hyperkalemia: Assess serum potassium before initiation and periodically thereafter.” |
| Warnings and precautions | “Hyponatremia: Assess serum sodium before initiation and periodically thereafter.” |
| Most common adverse reaction | “The most common adverse reaction (more frequent than placebo and ≥ 5% in BAXFENDY-treated patients) was hyperkalemia.” |
| Drug interactions | “Strong and moderate CYP3A inducers: Monitor the therapeutic effect of BAXFENDY more frequently during concomitant use.” |
| Renal impairment | “Safety and effectiveness of BAXFENDY initiated in patients with eGFR < 45 mL/min/1.73 m2 have not been established” |
| Elimination half-life | “The mean effective half-life of baxdrostat was approximately 26 hours (range 23 to 32 hours).” |
| Cardiovascular outcomes | “There are no controlled trials demonstrating risk reduction of these events with BAXFENDY.” |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Baxdrostat: BaxHTN primary endpoint in the prescribing information, seated systolic blood pressure at week 12

| Systolic blood pressure (mmHg) | BAXFENDY 2 mg | BAXFENDY 1 mg | Placebo |
| --- | --- | --- | --- |
| Participants | “n=266” | “n=264” | “n=263” |
| Baseline (mean) | “149.1” | “149.7” | “149.0” |
| Change from baseline (mean) | “-15.7” | “-14.5” | “-5.8” |
| Difference from placebo (95% CI) | “-9.8 (-12.6, -7.0)” | “-8.7 (-11.5, -5.8)” | |
| p-value vs. placebo | “< 0.0001” | “< 0.0001” | |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “The primary endpoints were change from baseline to Week 12 in seated office systolic blood pressure for BAXFENDY 2 mg once daily compared to placebo and for BAXFENDY 1 mg once daily compared to placebo.”
> “The change in mean systolic blood pressure during the 8-week randomized withdrawal period was -3.7 mmHg (95% CI -5.5, -1.9) in the BAXFENDY 2 mg arm and +1.4 mmHg (95% CI -1.2, 4.0) in the placebo arm, for a mean difference from placebo of -5.1 mmHg (95% CI -8.3, -1.9; p-value 0.002).”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Baxdrostat: BaxHTN publication

> “794 participants were randomized to and received baxdrostat 1mg (n=264), baxdrostat 2mg (n=266), or placebo (n=264) in addition to background therapy.”
> “Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively. Potassium >6.0 mmol/l occurred in 6 participants (2.3%) with baxdrostat 1mg, 8 (3.0%) with baxdrostat 2mg, and 1 (0.4%) with placebo.”

Source: [Flack et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618089/)

<a id="topic-2.1.2.14-7"></a>

### Baxdrostat: Bax24 trial, 24-hour ambulatory systolic blood pressure in resistant hypertension

> “At 12 weeks, the change from baseline in the least-squares mean 24 h ambulatory SBP was -16·6 mm Hg (95% CI -18·8 to -14·3) in the baxdrostat group (n=89) and -2·6 mm Hg (-4·7 to -0·4) in the placebo group (n=95); the estimated placebo-corrected difference was -14·0 mm Hg (-17·2 to -10·8; p<0·0001).”
> “A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-2.1.2.14-8"></a>

### Baxdrostat: adverse reactions in the pooled 12-week placebo-controlled periods

| Adverse reaction | BAXFENDY 2 mg (N=441), % | BAXFENDY 1 mg (N=333), % | Placebo (N=442), % |
| --- | --- | --- | --- |
| Hyperkalemia | “10.2” | “6.6” | “2.5” |
| Hypotension | “3.6” | “2.1” | “0.5” |
| Hyponatremia | “3.2” | “2.1” | “0.9” |
| Dizziness | “2.9” | “3.0” | “0.9” |
| Muscle spasms | “2.9” | “1.8” | “0.7” |

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “Hyperkalemia led to permanent discontinuation of treatment in 8 (1.8%) patients in the BAXFENDY 2 mg group, 2 (0.6%) patients in the BAXFENDY 1 mg group, and none in the placebo group.”
> “At Week 12, the mean placebo-corrected decrease in eGFR was 8.0 mL/min/1.73 m2 in the BAXFENDY 2 mg group and 7.1 mL/min/1.73 m2 in the BAXFENDY 1 mg group.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Baxdrostat: CHMP positive opinion in the European Union, November 2026

> “AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products.”
> “Baxfendy is approved in the US and other countries as a first-in-class ASI for adults with hypertension not adequately controlled on other therapies, with regulatory filings currently under review in other major regions, including Japan and China.”

Source: [AstraZeneca press release, Baxfendy EU CHMP opinion (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html)

<a id="topic-2.1.2.14-10"></a>

### Baxdrostat: anticipated FDA action date, December 2025, superseded by approval in May 2026

> “The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 2026 following use of a Priority Review voucher.”

Source: [AstraZeneca press release, baxdrostat NDA acceptance (2025)](https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html)

<a id="topic-2.1.2.14-11"></a>

### Aprocitentan (TRYVIO, Idorsia): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “TRYVIO is an endothelin receptor antagonist indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.” |
| Boxed warning | “WARNING: EMBRYO–FETAL TOXICITY” |
| Boxed warning | “Based on animal data TRYVIO may cause fetal harm if used by pregnant patients and is contraindicated in pregnancy.” |
| Recommended dosage | “The recommended dosage of TRYVIO is 12.5 mg orally once daily.” |
| Strengths | “Tablets: 12.5 mg” |
| Warnings and precautions | “ERAs cause hepatotoxicity and liver failure.” |
| Warnings and precautions | “Fluid retention may require intervention” |
| Most common adverse reactions | “Most common adverse reactions (more frequent than placebo and ≥ 2% in TRYVIO-treated patients) are edema/fluid retention and anemia.” |
| Fluid retention | “Edema/fluid retention was reported in 9% of TRYVIO-treated patients compared with 18% of patients receiving aprocitentan 25 mg (twice the recommended dose) and 2% on placebo in the clinical trial, requiring additional diuretic use in some patients.” |
| Hemoglobin | “A decrease in hemoglobin of >2 g/dL from baseline was observed in 7% of patients compared to 1% of placebo patients.” |
| Cardiovascular outcomes | “There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.” |

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Aprocitentan: PRECISION primary endpoint in the prescribing information, sitting systolic blood pressure at week 4

| Sitting systolic blood pressure (mmHg) | TRYVIO 12.5 mg | Placebo |
| --- | --- | --- |
| Participants | “243” | “244” |
| Baseline | “153.2” | “153.3” |
| LS mean change (97.5% CL) | “−15.4 (−17.5, −13.3)” | “−11.6 (−13.7, −9.5)” |
| Difference to placebo, LS mean (97.5% CL) | “−3.8 (−6.8, −0.8)” | “–” |
| p-value | “0.0043” | “–” |

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

> “The primary efficacy endpoint was the change in sitting SBP (SiSBP) from baseline to Week 4 during part 1, measured at trough by unattended automated office blood pressure (uAOBP).”
> “TRYVIO is not approved for use at a 25 mg dose.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

### Aprocitentan: REMS removed, April 2025

> “This Prior Approval sNDA provides for changes to the approved Tryvio label to remove text regarding the Tryvio REMS and proposed modifications to the approved Tryvio risk evaluation and mitigation strategy (REMS).”
> “a REMS is no longer required for Tryvio.”
> “04/02/2025”

Source: [FDA NDA 217686 supplement approval letter (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217686Orig1s004ltr.pdf)

<a id="topic-2.1.2.14-14"></a>

### Aprocitentan: commercial availability and approvals outside the United States

> “Aprocitentan is approved as TRYVIO® in the US for the treatment of systemic hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs, and has been commercially available since October 2024.”
> “Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, Switzerland, and Canada.”

Source: [Idorsia press release, aprocitentan commercialization partnership (2026)](https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3793976)

<a id="topic-2.1.2.14-15"></a>

### Spironolactone (ALDACTONE): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “ALDACTONE is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents.” |
| Dosage in essential hypertension | “The recommended initial daily dose is 25 to 100 mg of ALDACTONE administered in either single or divided doses is recommended.” |
| Titration | “Dosage can be titrated at two-week intervals.” |
| Strengths | “Tablets: 25 mg, 50 mg, and 100 mg” |
| Warnings and precautions | “ALDACTONE can cause hyperkalemia.” |
| Gynecomastia | “ALDACTONE can cause gynecomastia. In RALES, patients with heart failure treated with a mean dose of 26 mg of spironolactone once daily, about 9% of the male subjects developed gynecomastia.” |

Source: [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

### Spironolactone: PATHWAY-2 trial in drug-resistant hypertension

> “The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001)”
> “In six of the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

<a id="topic-2.1.2.14-17"></a>

### Eplerenone (INSPRA): prescribing information

| Field | Quoted label text |
| --- | --- |
| Indication | “INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure.” |
| Dosage in hypertension | “The recommended starting dose of INSPRA is 50 mg administered once daily.” |
| Dose increase | “For patients with an inadequate blood pressure response to 50 mg once daily increase the dosage of INSPRA to 50 mg twice daily.” |
| Contraindications for hypertension | “type 2 diabetes with microalbuminuria,” |
| Contraindications for hypertension | “creatinine clearance <50 mL/min, or” |
| Mechanism | “Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone” |

Source: [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

### Amiloride: randomized comparison with spironolactone in resistant hypertension

> “In this open-label, blinded end-point, randomized clinical trial involving 118 patients with resistant hypertension, amiloride and spironolactone lowered home-measured systolic blood pressure by 13.6 mm Hg and 14.7 mm Hg from baseline, respectively, with no difference in blood pressure–lowering effect.”
> “One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

> “While rates associated with amiloride treatment were unavailable, amiloride has an FDA boxed warning for hyperkalemia, either alone or in combination with hydrochlorothiazide.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-19"></a>

### Vicadrostat (BI 690517, Boehringer Ingelheim): investigational aldosterone synthase inhibitor studied with empagliflozin

> “Following a recommendation from the independent Data Monitoring Committee (DMC), Boehringer Ingelheim has decided to discontinue the EASi-KIDNEY trial (NCT06531824), one of four studies in the EASi program.”
> “Vicadrostat is an investigational compound and has not received marketing authorization in any country.”
> “EASi program contains three ongoing phase III studies: EASi-HF Preserved, EASi-HF-Reduced and EASi-PROTKT”

Source: [Boehringer Ingelheim press release, EASi-KIDNEY update (2026)](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial)

> “BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals.”

Source: [Tuttle et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38109916/)

<a id="topic-2.1.2.14-20"></a>

### Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen

> “The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was −12.1 mm Hg (95% CI, −16.5 to −7.6; P < .001) for indapamide, −9.7 mm Hg (95% CI, −12.9 to −6.6; P < .001) for amlodipine, and −4.5 mm Hg (95% CI, −8.2 to −0.8; P = .02) for olmesartan.”
> “Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention.”

Source: [Desai et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12120674/)

> “LSM differences vs placebo in change from baseline to month 3 were −14.1 mm Hg (95% CI, −19.2 to −9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; −16.7 mm Hg (95% CI, −21.2 to −12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and −15.7 mm Hg (95% CI, −20.8 to −10.6; P < .001) with zilebesiran, 600 mg, once every 6 months.”

Source: [Bakris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10873804/)

> “In this global multi-center Phase 3 ZENITH CVOT (NCT07181109), Alnylam and its partner Roche will enroll approximately 11,000 patients in 35 countries to evaluate zilebesiran (300 mg) administered every six months compared to placebo in patients with uncontrolled hypertension with either established CV disease or at high risk for CV disease despite the use of at least two or more antihypertensives.”

Source: [Alnylam press release, ZENITH first patient dosed (2025)](https://www.businesswire.com/news/home/20251001569564/en)

<a id="topic-2.1.2.14-21"></a>

### Renal denervation: FDA premarket approvals, November 2023

> “The Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “11/07/2023”

Source: [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023)

> “The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “11/17/2023”

Source: [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026)

<a id="topic-2.1.2.14-22"></a>

### Renal denervation: Medicare coverage with evidence development

> “The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.”
> “On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.1.2.14-23"></a>

### Renal denervation: sham-controlled trials

> “At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.”

Source: [Kandzari et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244969/)

> “The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle.”

Source: [Azizi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975904/)

> “RDN is an additional option to consider in managing resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.1.2.14-24"></a>

### Drug-level network meta-analysis in resistant hypertension: office systolic blood pressure

> “Ten RCTs including 2865 participants were analyzed.”
> “The MDs versus placebo were −14.08 mmHg for amiloride (95% CI, −17.40 to −10.77), −10.78 mmHg for spironolactone (95% CI, −13.14 to −8.42), −9.09 mmHg for baxdrostat (95% CI, −11.29 to −6.88), −8.14 mmHg for eplerenone (95% CI, −14.56 to −1.72), and −6.80 mmHg for lorundrostat (95% CI, −8.47 to −5.13).”
> “The MDs were −10.88 mmHg for MRAs (95% CI, −13.29 to −8.48) and −7.56 mmHg for ASIs (95% CI, −9.24 to −5.89).”
> “Although newer ASIs may provide meaningful short‐term BP reductions, equivalence with MRAs cannot be inferred from the current evidence.”
> “Finally, safety outcomes were not quantitatively compared because adverse event reporting was incomplete and inconsistent across trials.”

Source: [Tsou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13587145/)

<a id="topic-2.1.2.14-25"></a>

### Indirect comparison of lorundrostat and baxdrostat by the Bucher method

> “Five placebo-controlled RCTs (N = 2599) were included.”
> “The lower-dose pair was statistically equivalent (lorundrostat 50 mg vs. baxdrostat 1 mg: mean difference (MD), +0.63 mmHg; P = 0.645); baxdrostat 2 mg produced a modest but significant advantage over lorundrostat 100 mg (MD, +3.56 mmHg; P = 0.043).”
> “Both agents markedly increased hyperkalemia risk (lorundrostat pooled risk ratio (RR), 8.16; baxdrostat pooled RR, 15.12); the between-drug comparison was not significant.”

Source: [Yousif et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13754360/)

<a id="topic-2.1.2.14-26"></a>

### Bayesian meta-analysis of second-generation aldosterone synthase inhibitors

> “Eight RCTs were included (n = 3,369; 2,430 [72%] randomized to ASI).”
> “However, ASIs increased the odds of hyperkalemia (OR: 7.1; CrI: 3.56, 15.2; τ2 0.23), hyponatremia (OR: 2.6; CrI: 1.25, 5.98; τ2 0.1), and hypotension (OR: 3.28; CrI: 1.43, 8.16; τ2 0.1).”
> “In subgroup analysis, the probability of achieving a clinically meaningful reduction in SBP (MD < −5 mm Hg) was 87.5% with baxdrostat and 94.3% with lorundrostat.”

Source: [Queiroga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13100762/)

<a id="topic-2.1.2.14-27"></a>

### ICER network meta-analysis, Population 1 (resistant hypertension not at goal): systolic blood pressure versus placebo

| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
| --- | --- |
| Baxdrostat | “-11 (-14.6, -7.3)” |
| Spironolactone | “-10.1 (-13.1, -6.8)” |
| Lorundrostat | “-9 (-16.3, -1.7)” |
| Eplerenone | “-8.9 (-15.5, -2.4)” |
| Amiloride | “-6.6 (-11.5, -1.5)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Although treatment with baxdrostat or lorundrostat did not result in statistically significant decreases in SBP over spironolactone, eplerenone, or amiloride, 95% credible intervals were wide and included potentially clinically significant differences in both directions.”
> “Note: Each box represents the estimated treatment difference and 95% credible interval for the combined direct and indirect comparisons between two drugs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-28"></a>

### ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo

| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
| --- | --- |
| Baxdrostat | “-10.1 (-16.6, -3.9)” |
| Lorundrostat | “-8.6 (-12.4, -4.8)” |
| Amlodipine | “-8.3 (-10.7, -6.2)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, neither baxdrostat nor lorundrostat showed a statistically significant difference in SBP reduction compared with amlodipine, with very small differences between the drugs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-29"></a>

### ICER comparative evidence ratings

| Population | Treatment | Comparator | Evidence rating |
| --- | --- | --- | --- |
| “Populations 1 and 2” | “Baxdrostat” | “Lorundrostat” | “I” |
| “Populations 1 and 2” | “Baxdrostat or Lorundrostat” | “Spironolactone, Eplerenone, or Amiloride” | “P/I” |
| “Population 3” | “Baxdrostat” | “Lorundrostat” | “I” |
| “Population 3” | “Baxdrostat or Lorundrostat” | “Amlodipine” | “C-” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, ASIs such as baxdrostat and lorundrostat may be better tolerated than spironolactone and may result in greater blood pressure reductions than comparator drugs, though trials are only short-term.”
> “Finally, there are not yet data on the direct impact of baxdrostat and lorundrostat on patient-important outcomes such as cardiovascular events, kidney disease, dementia, quality of life, or mortality; the other comparators in our review have demonstrated a positive impact on patient-important outcomes.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-30"></a>

### Hyperkalemia at 12 weeks across aldosterone-pathway drugs

| Drug | Arm | n | Hyperkalemia, % |
| --- | --- | --- | --- |
| Baxdrostat | “BAX 1 mg” | “333” | “6.6” |
| Baxdrostat | “BAX 2 mg” | “441” | “10.2” |
| Baxdrostat | “Placebo” | “442” | “2.5” |
| Lorundrostat | “LOR 50 mg” | “635” | “2.5” |
| Lorundrostat | “Placebo” | “367” | “0.3” |
| Spironolactone | “SPIR 15-50 mg” | “2748” | “17.5” |
| Spironolactone | “Placebo” | “2760” | “7.5” |
| Eplerenone | “EPL 25-50 mg” | “5282” | “5” |
| Eplerenone | “Placebo” | “5275” | “2.6” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “However, use of MRA medications is often limited by side effects, most prominently hyperkalemia and gynecomastia.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.14-31"></a>

### Drug costs used by ICER for the comparators

| Drug | Net price per year |
| --- | --- |
| “Spironolactone (25 mg)” | “$43” |
| “Spironolactone (100 mg)” | “$171” |
| “Eplerenone (50 mg)” | “$511” |
| “Eplerenone (100 mg)” | “$1,022” |
| “Amiloride (5 mg)” | “$206” |
| “Amiloride (10 mg)” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets).”
> “For lorundrostat, we used the baxdrostat WAC price as a placeholder price.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

Additional sources: [Yusuf et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13232938/); [Elbahloul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41645642/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
